A little-noticed government policy shift caused a seven-year delay in choosing a costly medicine for Medicare price negotiations, an advocacy group says.
Little-noticed policy decision came at expense of taxpayers, Public Citizen says
Rachel Wisniewski for STAT
By Ed SilvermanAug. 6, 2026
Pharmalot Columnist, Senior Writer
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.
Adoption has been slow with new Alzheimer’s drugs because the treatments are complicated to administer and the benefits are…
CMS has proposed a policy to close what it says is a loophole that could help drugmakers avoid Medicare negotiations by making…
Pharma companies are facing pricing pressure from several directions, including from the U.S. Medicare negotiations
Millions could face steeper monthly costs
The subsidies are set to end a year ahead of schedule
Secret drug pricing deals, a virtual AI cancer clinic, and other biotech news from The Readout
